As of 2026-03-26, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (4,604.69) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -54272.9%.
The range of the Relative Valuation is (4,326.42) - (4,662.45) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.2x - 24.7x | 22.4x |
| Forward P/E multiples | 20.6x - 22.2x | 21.4x |
| Fair Price | (4,326.42) - (4,662.45) | (4,604.69) |
| Upside | -50999.0% - -54952.3% | -54272.9% |
| Date | P/E |